NVS
The table below shows Novartis AG's balance sheet line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & equivalents | - | - | - | - | - | - |
| Short-term investments | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Total current assets | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| - |
| - |
| Property, plant & equipment | - | - | - | - | - | - |
| Goodwill | $25.57B | $24.76B | $23.34B | $29.30B | $29.59B | $30.00B |
| Total assets | $110.95B | $102.25B | $99.94B | $117.45B | $131.79B | $132.06B |
| Accounts payable | - | - | - | - | - | - |
| Total current liabilities | - | - | - | - | - | - |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $64.40B | $58.12B | $53.20B | $58.03B | $63.97B | $75.39B |
| Retained earnings | - | - | - | - | - | - |
| Total equity | - | - | - | - | - | - |